OncoMatch/Clinical Trials/NCT06600698
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Is NCT06600698 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies INM176 for prostate cancer.
Treatment: INM176 — This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgery
Post-radical prostatectomy (RP)
Must have received: radiation therapy
post-radiation therapy (RT)
Must have received: antiandrogen
previous use of antiandrogen therapy
Lab requirements
Blood counts
Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count ≥ 1.0 x 10^9/L. INR, PT, and PTT within normal institutional limits
Kidney function
Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Chronic kidney disease with calculated GFR <30 mL/min/1.73 m2 using Cockcroft-Gault formula, or measured GFR <30 mL/min/1.73 m2 using a 24-hour urine collection [excluded]
Liver function
Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN)
Subjects must have normal liver and kidney function at baseline: Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN). Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Adequate bone marrow function: Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count of ≥ 1.0 x 10^9/L). International Normalized Ratio (INR), Prothrombin Time (PT), and Partial Thromboplastin Time (PTT) within normal institutional limits.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Penn State Cancer Institute · Hershey, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06600698 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery and radiation therapy.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages